NCT00159666

Study of Pregabalin Therapy for Pain Relief in Subjects With Post-Herpetic Neuralgia

A Double-Blind Randomized Placebo-Controlled Trial of the Time to Onset of Pain Relief in Subjects With Post Therapeutic Neuralgia (PHN) Treated With Pregabalin (150 - 600 Mg/Day Flexible Optimized Dose or 300 Mg/Day Fixed Dose) or Placebo

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 255 (planned)
• Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to measure how rapidly pregabalin treatment can relieve pain in patients with post-herpetic neuralgia

Conditions

• Post-Herpetic Neuralgia

Interventions

Type	Name	Description
DRUG	pregabalin

Timeline

• Start date: 2004-10-01
• Completion: 2006-06-01
• First posted: 2005-09-12
• Last updated: 2021-01-22

Locations

40 sites across 5 countries: United States, Germany, Italy, Spain, United Kingdom